NO20030304L - Ny kombinasjon av serotoninagonist (5HT2) og antagonist (5HT6) som farmasoytisk formulering - Google Patents

Ny kombinasjon av serotoninagonist (5HT2) og antagonist (5HT6) som farmasoytisk formulering

Info

Publication number
NO20030304L
NO20030304L NO20030304A NO20030304A NO20030304L NO 20030304 L NO20030304 L NO 20030304L NO 20030304 A NO20030304 A NO 20030304A NO 20030304 A NO20030304 A NO 20030304A NO 20030304 L NO20030304 L NO 20030304L
Authority
NO
Norway
Prior art keywords
antagonist
pharmaceutical formulation
new combination
serotonin agonist
serotonin
Prior art date
Application number
NO20030304A
Other languages
English (en)
Norwegian (no)
Other versions
NO20030304D0 (no
Inventor
Sukhwinder Jossan
Bjoern M Nilsson
Kjell S Sakariassen
Jan Svartengren
Original Assignee
Biovitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovitrum Ab filed Critical Biovitrum Ab
Publication of NO20030304D0 publication Critical patent/NO20030304D0/no
Publication of NO20030304L publication Critical patent/NO20030304L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
NO20030304A 2000-07-21 2003-01-20 Ny kombinasjon av serotoninagonist (5HT2) og antagonist (5HT6) som farmasoytisk formulering NO20030304L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0002754A SE0002754D0 (sv) 2000-07-21 2000-07-21 New pharmaceutical combination formulation and method of treatment with the combination
PCT/SE2001/001651 WO2002008178A1 (en) 2000-07-21 2001-07-19 New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation

Publications (2)

Publication Number Publication Date
NO20030304D0 NO20030304D0 (no) 2003-01-20
NO20030304L true NO20030304L (no) 2003-03-12

Family

ID=20280577

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030304A NO20030304L (no) 2000-07-21 2003-01-20 Ny kombinasjon av serotoninagonist (5HT2) og antagonist (5HT6) som farmasoytisk formulering

Country Status (19)

Country Link
EP (1) EP1301476A1 (xx)
JP (1) JP2004504376A (xx)
KR (1) KR100845450B1 (xx)
CN (1) CN1221254C (xx)
AU (2) AU2001282734B2 (xx)
BR (1) BR0112661A (xx)
CA (1) CA2411192A1 (xx)
EA (1) EA006604B1 (xx)
HK (1) HK1057536A1 (xx)
HU (1) HUP0301346A3 (xx)
IL (1) IL154057A0 (xx)
MX (1) MXPA03000548A (xx)
NO (1) NO20030304L (xx)
NZ (1) NZ523216A (xx)
PL (1) PL360309A1 (xx)
SE (1) SE0002754D0 (xx)
WO (1) WO2002008178A1 (xx)
YU (1) YU2603A (xx)
ZA (1) ZA200210234B (xx)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2298738B1 (en) * 2000-11-02 2012-09-19 Wyeth LLC 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
US7034029B2 (en) 2000-11-02 2006-04-25 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
CN1321110C (zh) * 2001-06-15 2007-06-13 弗·哈夫曼-拉罗切有限公司 具有5－ht6受体亲和力的4－哌嗪基吲哚衍生物
MXPA03011638A (es) * 2001-06-15 2004-04-02 Hoffmann La Roche Nuevos derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6.
US6825198B2 (en) 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
GB0202679D0 (en) * 2002-02-05 2002-03-20 Glaxo Group Ltd Novel compounds
DK1497266T3 (da) * 2002-03-27 2008-10-06 Glaxo Group Ltd Quinolinderivater og deres anvendelse som 5HT6-ligander
CL2004000826A1 (es) * 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
US8754238B2 (en) 2003-07-22 2014-06-17 Arena Pharmaceuticals, Inc. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
EP2400300A1 (en) 2004-08-25 2011-12-28 Takeda Pharmaceutical Company Limited Method of screening preventives/remedies for stress urinary incontinence
US7713954B2 (en) 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
US20100048713A1 (en) * 2006-01-06 2010-02-25 Aarhus Universitet Compounds acting on the serotonin transporter
EP2727585A1 (en) 2006-05-16 2014-05-07 Takeda Pharmaceutical Company Limited In-vivo screening method
US20070293475A1 (en) * 2006-06-20 2007-12-20 Alcon Manufacturing Ltd. Aryl and heteroaryl tetrahydrobenzazepine derivatives and their use for treating glaucoma
DE602007012080D1 (de) * 2007-08-01 2011-03-03 Esteve Labor Dr Kombination von mindestens zwei 5-HT6-Liganden
US20100266504A1 (en) 2007-11-15 2010-10-21 Takahiro Matsumoto Condensed pyridine derivative and use thereof
US9084742B2 (en) 2007-12-12 2015-07-21 Axovant Sciences Ltd. Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
UA100192C2 (xx) 2008-11-11 2012-11-26 УАЙТ ЭлЭлСи 1-(арилсульфоніл)-4-(піперазин-1-іл)-1h-бензімідазоли як ліганди 5-гідрокситриптаміну-6$1-(арилсульфонил)-4-(пиперазин-1-ил)-1h-бензимидазолы как лиганды 5-гидрокситриптамина-6
TWI542592B (zh) 2009-06-15 2016-07-21 武田藥品工業股份有限公司 吡並氮雜氧雜環庚烯衍生物
JPWO2011071136A1 (ja) 2009-12-11 2013-04-22 アステラス製薬株式会社 線維筋痛症治療剤
KR20180022792A (ko) 2015-06-12 2018-03-06 엑소반트 사이언시즈 게엠베하 렘 수면 행동 장애의 예방 및 치료에 유용한 디아릴 및 아릴헤테로아릴 우레아 유도체
BR112018000728A2 (pt) 2015-07-15 2018-09-04 Axovant Sciences Gmbh resumo método para a profilaxia e/ou tratamento de alucinações visuais em um sujeito com necessidade do mesmo
CN107628981B (zh) * 2017-10-31 2019-07-30 威海市妇女儿童医院 一种肉桂酰基吲哚啉化合物及其制备青光眼药物的应用
EP3733204A4 (en) 2017-12-27 2021-09-15 Takeda Pharmaceutical Company Limited THERAPEUTIC FOR EXERCISE INCONTINENCE AND STAIR INCONTINENCE
CN111269165A (zh) * 2018-12-05 2020-06-12 中国科学院大连化学物理研究所 一种3-芳基磺酰基吲哚衍生物的合成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
GB9803411D0 (en) * 1998-02-18 1998-04-15 Smithkline Beecham Plc Novel compounds
US6100291A (en) * 1998-03-16 2000-08-08 Allelix Biopharmaceuticals Inc. Pyrrolidine-indole compounds having 5-HT6 affinity
US6251893B1 (en) * 1998-06-15 2001-06-26 Nps Allelix Corp. Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
GB9819035D0 (en) * 1998-09-01 1998-10-28 Cerebrus Res Ltd Chemical compounds VII

Also Published As

Publication number Publication date
WO2002008178A1 (en) 2002-01-31
PL360309A1 (en) 2004-09-06
NZ523216A (en) 2005-05-27
EA006604B1 (ru) 2006-02-24
EA200300183A1 (ru) 2003-08-28
EP1301476A1 (en) 2003-04-16
KR100845450B1 (ko) 2008-07-10
ZA200210234B (en) 2004-03-18
AU8273401A (en) 2002-02-05
CA2411192A1 (en) 2002-01-31
HK1057536A1 (en) 2004-04-08
NO20030304D0 (no) 2003-01-20
MXPA03000548A (es) 2004-04-05
JP2004504376A (ja) 2004-02-12
YU2603A (sh) 2006-05-25
IL154057A0 (en) 2003-07-31
CN1443162A (zh) 2003-09-17
CN1221254C (zh) 2005-10-05
BR0112661A (pt) 2003-06-24
HUP0301346A3 (en) 2005-05-30
SE0002754D0 (sv) 2000-07-21
AU2001282734B2 (en) 2006-10-12
KR20030036599A (ko) 2003-05-09
HUP0301346A2 (hu) 2003-08-28

Similar Documents

Publication Publication Date Title
NO20030304L (no) Ny kombinasjon av serotoninagonist (5HT2) og antagonist (5HT6) som farmasoytisk formulering
NO2023030I1 (no) Apixaban and pharmaceutical acceptable salts thereof
NO20032797L (no) Substituerte pyridoindoler som serotonin agonister og antagonister
DK1454901T3 (da) Farmaceutiske sammensætninger omfattende tachykininantagonister og en serotoningenoptagelseshæmmer
NO20031744D0 (no) Nye ikke-imadazolforbindelser og farmasöytisk preparat omfattende slike
EE200300284A (et) NMDA-retseptori agonisti farmatseutilised kompositsioonid
NO20025450L (no) Ny farmasöytisk sammensetning
CY2007013I2 (el) Νεες συνταγοποιησεις αγωνιστου εξεντινης και μεθοδοι χορηγησης αυτων
ATE431145T1 (de) Missbrauchssichere orale opioid-agonist zubereitungen
DE60212044D1 (de) Test der bukkalen Auflösung pharmazeutisch aktiver Stoffe
NO20030471D0 (no) Karboksamidforbindelser og deres anvendelse som antagonister for en 11CBY-reseptor
DK1263721T3 (da) Farmaceutiske sammensætninger, der indeholder 3-aminoazetidinderivater, nye derivater og fremstilling deraf
HUP0402313A3 (en) Phenyl-piperazine derivatives as serotonin reuptake inhibitors, pharmaceutical compositions containing them and use thereof
NO20032517D0 (no) Farmasöytisk preparat inneholdende amlodipinmaleat
DK1463716T3 (da) Pyrrolidin- og piperidinderivater som NK1-antagonister
NO20011503L (no) Indeno-, nafto- og benzocyklohepta-dihydrotiazolderivater, deres fremstilling og anvendelse som anorektiske legemidler
NO20041008L (no) Karbazolderivater og anvendelse derav som NPY5 reseptor antagonister
NO20041607L (no) Doseringsregime og farmasoytisk preparat for nodprevensjon
NO20032142D0 (no) Substituerte 2-fenylaminoimidazolin-fenylketon-derivater som IP-antagonister
DK1230230T3 (da) Derivater af indeno-dihydrothiazol, fremstilling deraf og anvendelse som anorektiske lægemidler
DK1322158T3 (da) Farmaceutiske præparater med langvarig frigivelse, som indeholder metformin, og fremgangsmåde til fremstilling deraf
NO20040254L (no) Farmasoytiske sammensetninger som inneholder terbinafin og anvendelse derav
NO20043124L (no) Aminoindanderivater som serotonin -og norepinefrin-opptaksinhibitorer
NO20030382D0 (no) Nye indolderivater og deres anvendelse som medikamenter
HUP0300419A3 (en) Estrogen agonist/antagonist metabolites, pharmaceutical compositions containing them and their use

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application